Follistatin-344

Follistatin-344 (FST-344) – Myostatin & Activin Research Protein

Follistatin Precursor for TGF-β Signaling, Skeletal Muscle Biology & Growth Factor Regulation Research

Follistatin-344 (FST-344) is a naturally occurring protein precursor encoded by the human FST gene. It is associated with the production of follistatin-315, a secreted glycoprotein that participates in the regulation of several members of the transforming growth factor-beta (TGF-β) superfamily.

Follistatin is best known for its ability to bind and neutralize selected extracellular signaling proteins, including activins and myostatin (GDF-8).

These interactions make follistatin an important subject in experimental research involving skeletal muscle development, cellular differentiation, endocrine regulation and growth factor signaling.

Follistatin-344 has also been investigated in experimental gene-transfer strategies designed to increase follistatin expression in specific tissues.

However, findings involving follistatin gene therapy cannot automatically be applied to purified follistatin protein preparations marketed for laboratory research.

ICAME Pharmacy Follistatin-344 is intended strictly for laboratory research and development purposes. Not for human or veterinary use.

What Is Follistatin-344?

Follistatin is a secreted, cysteine-rich glycoprotein originally identified through research on reproductive hormones.

Its name derives from its ability to suppress the secretion of follicle-stimulating hormone (FSH) through the neutralization of activin-associated signaling.

Subsequent investigations established that follistatin participates in a much broader range of biological processes.

These include:

• Myostatin regulation

• Activin signaling

• Skeletal muscle biology

• Cellular growth and differentiation

• Reproductive endocrinology

• Tissue remodeling

• Developmental biology

• TGF-β superfamily signaling

• Experimental gene therapy

Follistatin is not a direct androgen, anabolic steroid or growth hormone analogue.

Its biological effects arise primarily from its interactions with extracellular signaling proteins.

Follistatin-344 Molecular Structure

Human follistatin is encoded by the FST gene, located on chromosome 5.

Alternative RNA splicing produces distinct follistatin precursor isoforms.

The two principal precursor forms are:

FST-344: A 344-amino-acid precursor.

FST-317: A 317-amino-acid precursor.

These precursor proteins undergo post-translational processing.

A 29-amino-acid N-terminal signal peptide is removed during maturation.

Follistatin Processing

FST Gene

↓

Alternative RNA Splicing

↓

FST-344 Precursor — 344 Amino Acids

↓

Removal of 29-Amino-Acid Signal Peptide

↓

Mature FST-315 — 315 Amino Acids

The alternative FST-317 precursor produces mature FST-288 after signal peptide removal.

These distinctions are essential when interpreting product specifications and scientific studies.

Follistatin-344 vs. Follistatin-315

Follistatin-344 and follistatin-315 are closely related but represent different stages of protein processing.

Important: The term Follistatin-344 is also commonly used to describe the coding sequence incorporated into experimental gene therapy constructs.

This does not mean that the circulating protein produced by those constructs retains all 344 amino acids.

Follistatin Isoforms: FST-344, FST-315, FST-288 and FST-303

Follistatin exists in several molecular forms with distinct biological characteristics.

FST-344

The longer precursor protein encoded by one major FST transcript.

FST-315

The mature protein produced from FST-344 following removal of its signal peptide.

FST-315 is generally associated with soluble, circulating follistatin activity.

FST-317

An alternatively spliced precursor protein.

FST-288

The mature protein produced from FST-317.

FST-288 exhibits relatively strong interactions with cell-surface heparan sulfate proteoglycans.

FST-303

An intermediate form that may arise through additional proteolytic processing of FST-315.

Differences between these isoforms influence their localization, extracellular interactions and biological activity.

How Does Follistatin Work?

Follistatin functions primarily as an extracellular ligand-binding protein.

Rather than directly activating a conventional cell-surface receptor, follistatin binds certain signaling proteins and can prevent them from interacting with their receptors.

Important binding partners include:

Activin A

Activin B

Myostatin (GDF-8)

Selected Bone Morphogenetic Proteins (BMPs)

The strength and biological consequences of these interactions depend on the follistatin isoform, ligand, tissue and experimental conditions.

Simplified Mechanism

Follistatin

↓

Binding to Selected TGF-β Superfamily Ligands

↓

Reduced Ligand Availability for Cell-Surface Receptors

↓

Changes in Downstream SMAD Signaling

↓

Altered Cellular Responses

This mechanism is important in several areas of experimental biology.

Follistatin and Myostatin (GDF-8)

Myostatin, also known as growth differentiation factor 8 (GDF-8), is a member of the TGF-β superfamily.

It plays an important role in the regulation of skeletal muscle growth.

Myostatin-associated signaling generally acts to restrain excessive muscle growth.

Follistatin can bind myostatin and reduce its ability to activate downstream signaling.

Myostatin Signaling Pathway

Myostatin (GDF-8)

↓

Activin Type II Receptors

↓

Type I Receptor Activation

↓

SMAD2/3 Signaling

↓

Regulation of Skeletal Muscle Growth

When follistatin binds myostatin, it can reduce the availability of the ligand for receptor activation.

This interaction has generated scientific interest in follistatin as a potential regulator of skeletal muscle biology.

However, follistatin's effects are not limited to myostatin, and systemic changes in related signaling pathways may have unintended consequences.

Follistatin and Activin A

Activin A is another member of the TGF-β superfamily.

It participates in numerous physiological processes, including:

• Reproductive hormone regulation

• Cellular differentiation

• Tissue development

• Inflammatory signaling

• Fibrosis-related biology

• Skeletal muscle physiology

Follistatin was originally identified because of its ability to neutralize activin and influence FSH secretion.

The interaction between follistatin and activin remains one of its best-characterized biological functions.

Follistatin isoforms differ in their interactions with the extracellular environment, which can alter their capacity to regulate local activin signaling.

Follistatin and TGF-β/SMAD Signaling

The TGF-β superfamily includes a large group of signaling proteins involved in growth, differentiation and tissue homeostasis.

Many of these ligands act through serine/threonine kinase receptors and intracellular SMAD proteins.

Myostatin and activins commonly signal through pathways involving SMAD2 and SMAD3.

Follistatin can influence these pathways by binding the extracellular ligands before they engage their receptors.

Research areas include:

Ligand–receptor interactions

SMAD2/3 signaling

Extracellular growth factor regulation

Cellular differentiation

Tissue remodeling

Skeletal muscle development

Follistatin is therefore relevant to the study of extracellular signaling control.

Follistatin-344 and Skeletal Muscle Research

Skeletal muscle tissue is regulated by multiple interacting biological systems.

These include growth factors, mechanical signals, metabolic pathways and satellite cell activity.

Myostatin is one of the best-known negative regulators of skeletal muscle growth.

Follistatin has been investigated because of its capacity to antagonize myostatin-associated signaling.

Experimental research has examined:

• Muscle fiber size

• Muscle mass regulation

• Myogenic differentiation

• Satellite cell biology

• Muscle regeneration

• Muscle-associated gene expression

• Growth factor signaling

Some preclinical studies have reported increased muscle mass following follistatin overexpression or experimental gene transfer.

These results do not establish that a commercially supplied research protein produces equivalent outcomes in humans.

Follistatin and Muscle Fiber Biology

Skeletal muscle is composed of specialized contractile fibers.

Muscle fiber size and function are influenced by numerous biological pathways.

Research involving myostatin and follistatin has examined how extracellular signaling influences muscle tissue.

Relevant endpoints include:

Muscle fiber cross-sectional area

Myogenic differentiation

Muscle protein regulation

Cellular growth

Tissue remodeling

Muscle-associated signaling

Follistatin research has contributed to understanding how TGF-β superfamily ligands participate in muscle development.

However, muscle hypertrophy observed in animal models cannot automatically be generalized to healthy humans.

Follistatin and Satellite Cell Research

Satellite cells are muscle-resident stem cells involved in skeletal muscle maintenance and repair.

They contribute to muscle regeneration following certain types of tissue injury.

Their activity is regulated by growth factors, inflammatory signals and local tissue conditions.

Myostatin-associated signaling has been investigated in relation to satellite cell function.

Follistatin may be relevant to experimental studies examining how ligand neutralization influences the cellular environment associated with muscle repair.

However, follistatin has not been established as a clinically approved treatment for muscle injury or recovery.

Follistatin-344 and Experimental Gene Therapy

One of the most extensively investigated applications of the FST-344 coding sequence involves experimental gene transfer.

In this approach, a gene-delivery vector carries genetic instructions for follistatin expression.

Researchers have investigated adeno-associated virus (AAV) vectors encoding FST-344.

After cellular expression and processing, the encoded precursor produces mature follistatin.

Experimental Gene Expression Pathway

AAV Vector Carrying FST-344 Coding Sequence

↓

Cellular Expression of FST-344 Precursor

↓

Signal Peptide Processing

↓

Production of Mature FST-315

↓

Extracellular Ligand Binding

↓

Experimental Modulation of Myostatin/Activin Signaling

This research approach is fundamentally different from studying an isolated protein preparation.

Gene therapy findings cannot be used as direct evidence for the efficacy of a separately manufactured research protein.

Follistatin Gene Therapy and Becker Muscular Dystrophy

Becker muscular dystrophy (BMD) is a genetic muscle disorder associated with abnormalities in the dystrophin protein.

Researchers have investigated follistatin gene transfer as a possible experimental strategy for muscle disease.

A small phase 1/2a study evaluated an AAV1 vector carrying the FST-344 coding sequence in six individuals with Becker muscular dystrophy.

The study reported improvements in six-minute walk distance in four participants, while two participants showed no improvement.

The findings were considered encouraging for further research.

However, the study was small, uncontrolled and designed primarily to investigate feasibility and safety.

It did not establish that follistatin gene therapy is a proven treatment for Becker muscular dystrophy.

Importantly, the findings concerned gene transfer, not administration of a commercial Follistatin-344 research protein.

Follistatin and Neuromuscular Disease Research

Follistatin-associated research has also explored other muscle disorders.

These include:

Muscular dystrophy research

Sporadic inclusion body myositis

Muscle degeneration models

Experimental muscle regeneration

Neuromuscular disease biology

The scientific interest is based partly on the possibility of modifying growth-factor signaling in skeletal muscle.

However, clinical development remains investigational, and outcomes vary across different experimental approaches.

Follistatin and Reproductive Endocrinology

Follistatin was originally identified in reproductive physiology research.

Activin stimulates pituitary FSH production through specific signaling pathways.

Follistatin can bind activin and reduce its availability.

This makes follistatin relevant to research involving:

• Follicle-stimulating hormone regulation

• Pituitary endocrine signaling

• Ovarian physiology

• Testicular physiology

• Gonadal development

• Reproductive tissue biology

Because activin participates in multiple reproductive functions, broad inhibition of activin-associated signaling may create safety concerns.

Different follistatin isoforms exhibit distinct patterns of tissue localization and biological activity.

Follistatin and Tissue Remodeling

Tissue remodeling involves changes in extracellular matrix structure, cellular organization and growth factor signaling.

Members of the TGF-β superfamily contribute to these processes.

Follistatin has been investigated in experimental models involving:

Fibrosis-associated signaling

Cellular differentiation

Extracellular matrix regulation

Tissue development

Repair-associated pathways

However, the biological consequences of follistatin activity depend on the specific tissue and signaling environment.

It should not be described as a universally beneficial tissue-repair protein.

Follistatin and Metabolic Research

Skeletal muscle plays an important role in whole-body metabolism.

It contributes to glucose disposal, energy expenditure and protein turnover.

Because follistatin influences pathways involved in muscle biology, researchers have investigated its relationship with metabolic regulation.

Relevant research topics include:

Skeletal muscle metabolism

Myostatin-associated signaling

Adipose tissue biology

Energy balance

Glucose regulation

Growth factor interactions

Some preclinical studies have explored follistatin-associated changes in adipose tissue and metabolic phenotypes.

These findings do not establish follistatin as an effective or safe treatment for obesity or metabolic disorders in humans.

Follistatin and Aging-Related Muscle Biology

Aging is associated with complex changes in skeletal muscle mass, strength and physical function.

These processes involve neurological, endocrine, inflammatory and metabolic factors.

Myostatin and activin signaling have been investigated in the context of age-associated muscle changes.

Follistatin research may therefore be relevant to the study of:

Muscle aging

Sarcopenia-related pathways

Muscle protein regulation

Growth factor signaling

Functional muscle biology

However, there is insufficient evidence to establish Follistatin-344 research preparations as effective interventions for age-related muscle loss or longevity.

Follistatin and Cancer Biology

Follistatin's biological activity extends beyond skeletal muscle.

Activins and related TGF-β superfamily ligands can influence cellular growth, differentiation and tumor biology.

Follistatin has been investigated in several cancer-related research contexts.

Its effects may differ depending on the tumor type, surrounding tissues and signaling environment.

In some experimental systems, follistatin-associated signaling has been linked to processes relevant to tumor progression or treatment response.

Consequently, long-term or systemic manipulation of follistatin pathways cannot be assumed to be harmless.

This is an important consideration when interpreting claims about muscle growth or regenerative applications.

Follistatin-344 vs. Myostatin Inhibitors

Follistatin is sometimes described as a myostatin inhibitor.

However, its biological activity is broader than direct myostatin neutralization.

The broad ligand-binding activity of follistatin is scientifically important but may complicate safety and selectivity.

Follistatin-315 vs. Follistatin-288

The two major mature follistatin isoforms exhibit important differences.

These differences help explain why follistatin isoform identity matters in experimental studies.

Scientific Evidence and Research Limitations

Follistatin is a well-characterized biological protein.

Its interactions with activin and myostatin are supported by extensive biochemical research.

However, important distinctions must be maintained.

Established Biological Findings

• Follistatin is encoded by the FST gene.

• Alternative splicing produces distinct precursor isoforms.

• FST-344 is processed to mature FST-315.

• Follistatin binds activins and myostatin.

• Follistatin isoforms differ in localization and biological behavior.

• Experimental modulation of follistatin pathways can influence muscle biology.

Important Research Limitations

• Findings from gene therapy cannot be transferred directly to purified protein products.

• Human clinical evidence remains limited and application-specific.

• Effects on healthy human muscle growth are not established for research-grade products.

• Broad activin and myostatin modulation may produce unintended effects.

• The identity, purity, folding and biological activity of commercial preparations require independent verification.

• Long-term systemic safety has not been established for unapproved follistatin preparations.

Potential Research Applications

Follistatin-344 may be relevant to appropriately controlled investigations involving:

• Myostatin (GDF-8) biology

• Activin A and activin B signaling

• TGF-β superfamily regulation

• SMAD2/3 signaling

• Skeletal muscle development

• Muscle fiber biology

• Myogenic differentiation

• Satellite cell research

• Muscle regeneration models

• Neuromuscular disease research

• Follistatin isoform processing

• Protein biosynthesis

• Growth factor binding

• Reproductive endocrinology

• Pituitary FSH regulation

• Tissue remodeling

• Experimental gene therapy

• Metabolic signaling

• Aging-related muscle biology

• Extracellular ligand regulation

These represent scientific research fields rather than proven clinical benefits.

Follistatin-344 Research Overview

Compound Name: Follistatin-344

Abbreviation: FST-344 / FS344

Classification: Follistatin Protein Precursor

Precursor Length: 344 Amino Acids

Mature Processed Isoform: FST-315

Mature Isoform Length: 315 Amino Acids

Encoding Gene: FST

Primary Ligand Interactions: Activins / Myostatin

Principal Research Pathways: TGF-β Superfamily / SMAD Signaling

Research Fields: Muscle Biology / Endocrinology / Protein Processing

Clinical Status: Investigational research; no general-purpose therapeutic approval for Follistatin-344 research preparations

Product Information

Product Name: Follistatin-344

Brand: ICAME Pharmacy

Product Category: Research Protein / Peptide Research Product

Research Classification: Follistatin Precursor-Associated Research Material

Research Areas: Myostatin Signaling / Activin Biology / Skeletal Muscle Research

Intended Use: Laboratory Research & Development Only

The designation Follistatin-344 does not, by itself, establish the molecular form of the material supplied.

Before publication, the manufacturer should confirm whether the product contains:

Full-length FST-344 precursor protein

Mature FST-315 protein

Another recombinant follistatin construct or fragment

An FST-344 gene-expression material

These are distinct research materials and should not be described interchangeably.

Relevant batch-specific documentation should include:

• Verified molecular identity

• Amino acid sequence

• Mature or precursor protein designation

• Recombinant expression system, if applicable

• Protein purity

• Protein folding and structural characterization, where available

• Glycosylation status, where relevant

• Biological activity assay, if claimed

• Certificate of Analysis (COA)

• Batch/lot identification

• Validated storage conditions

Protein identity and functional activity should be supported by appropriate analytical methods rather than assumed from the product name.

Important Research Use Notice

FOR RESEARCH USE ONLY (RUO)

This ICAME Pharmacy product is intended exclusively for legitimate laboratory, analytical and scientific research purposes.

Not for human or veterinary use. Not for diagnostic, therapeutic, muscle-building, performance-enhancing, weight-management, anti-aging or other clinical purposes. Not for direct administration to humans or animals.

Follistatin participates in multiple growth factor and endocrine signaling pathways.

Manipulating myostatin and activin activity may have consequences beyond skeletal muscle biology.

Findings from experimental gene therapy studies do not establish the safety, efficacy or pharmaceutical equivalence of ICAME Pharmacy research materials.

Information presented on this page is intended solely for scientific and educational purposes and does not constitute medical advice, prescribing information, dosage guidance or instructions for human use.

About ICAME Pharmacy

ICAME Pharmacy provides specialized research products for professional laboratory and scientific applications.

Our portfolio focuses on compounds relevant to peptide science, protein biology, molecular signaling, endocrinology, experimental pharmacology and life sciences research.

We emphasize accurate product identification, responsible research use, scientific transparency and clear communication of evidence limitations.

For batch-specific analytical documentation and product inquiries, please contact ICAME Pharmacy.